Among all MK AML patients in the study, 108 (69.2%) had TP53 Mut (MK AML TP53 Mut), while 48 (30.8%) were MK AML TP53 wild-type (MK AML TP53 WT). The gene discussed is TP53; the disease is acute myeloid leukemia.